Alcon Past Earnings Performance

Past criteria checks 5/6

Alcon has been growing earnings at an average annual rate of 65.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 7.2% per year. Alcon's return on equity is 5.4%, and it has net margins of 11.9%.

Key information

65.3%

Earnings growth rate

65.2%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate7.2%
Return on equity5.4%
Net Margin11.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Sep 04

Alcon: Trading At An Undeserved Premium Valuation

Aug 01

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

May 14

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Oct 10

Alcon: Lackluster Growth Given Its Valuation

Jul 26

Alcon: The Steady Force Of 'Boring'

Jun 27

Alcon reached $199M settlement with J&J Surgical Vision

Feb 13

Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings

Feb 01

Alcon a buy at Mizuho on 'eyecare dominance'

Dec 22

Alcon Q3 2022 Earnings Preview

Nov 14

Alcon: Looking To Break Downtrend Before Entry

Sep 04

Alcon downgraded to hold at Societe Generale on macro headwinds

Aug 11

Alcon: Revisiting The Investment Thesis

Jun 03

The Recent Pullback Makes Alcon More Attractive

Mar 18

Alcon: Good Quarterly Results, But It Is Still Expensive

Dec 22

Looking At Alcon Through A Different Lens

Sep 11

Alcon Inc. 2021 Q1 - Results - Earnings Call Presentation

May 06

Alcon to acquire U.S. commercialization rights to ophthalmic eye drops Simbrinza from Novartis

Apr 28

Alcon: Global Leader In An Attractive End-Market

Dec 16

Revenue & Expenses Breakdown

How Alcon makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:ALC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,7611,1613,242860
30 Jun 249,6361,1023,231836
31 Mar 249,5621,0483,226842
31 Dec 239,4559743,209845
30 Sep 239,2744503,177837
30 Jun 239,0853623,141795
31 Mar 238,8803413,112759
31 Dec 228,7173353,068723
30 Sep 228,6955713,131684
30 Jun 228,6574573,145706
31 Mar 228,5504603,125703
31 Dec 218,2913763,076703
30 Sep 218,0823322,980706
30 Jun 217,8181832,884680
31 Mar 216,922-3902,690665
31 Dec 206,833-5312,694675
30 Sep 206,806-7172,647678
30 Jun 206,836-6362,662702
31 Mar 207,525-6042,827707
31 Dec 197,508-6562,802690
30 Sep 197,386-6382,830735
30 Jun 197,280-7792,827688
31 Mar 197,177-3622,761665
31 Dec 187,153-2272,799653
30 Sep 187,1231752,725527
31 Dec 176,7922562,596545
31 Dec 166,596-1702,526481
31 Dec 156,7763082,337457

Quality Earnings: ALC has high quality earnings.

Growing Profit Margin: ALC's current net profit margins (11.9%) are higher than last year (4.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALC has become profitable over the past 5 years, growing earnings by 65.3% per year.

Accelerating Growth: ALC's earnings growth over the past year (158%) exceeds its 5-year average (65.3% per year).

Earnings vs Industry: ALC earnings growth over the past year (158%) exceeded the Medical Equipment industry 10.4%.


Return on Equity

High ROE: ALC's Return on Equity (5.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies